Transplantation for multiple myeloma: Who, when, how often?

Joan Bladé; David H. Vesole; Morie Gertz

doi:10.1182/blood-2003-01-0073

Transplantation for multiple myeloma: Who, when, how often?

Joan Bladé, David H. Vesole, Morie Gertz

Hematology

Research output: Contribution to journal › Review article › peer-review

76 Scopus citations

Abstract

The outcome of phtients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.^1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.^3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS). Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.

Original language	English (US)
Pages (from-to)	3469-3477
Number of pages	9
Journal	Blood
Volume	102
Issue number	10
DOIs	https://doi.org/10.1182/blood-2003-01-0073
State	Published - Nov 15 2003

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2003-01-0073

Cite this

@article{da810be24061454b8fd87d45dfada7b9,

title = "Transplantation for multiple myeloma: Who, when, how often?",

abstract = "The outcome of phtients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS). Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.",

author = "Joan Blad{\'e} and Vesole, {David H.} and Morie Gertz",

year = "2003",

month = nov,

day = "15",

doi = "10.1182/blood-2003-01-0073",

language = "English (US)",

volume = "102",

pages = "3469--3477",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "10",

}

TY - JOUR

T1 - Transplantation for multiple myeloma

T2 - Who, when, how often?

AU - Bladé, Joan

AU - Vesole, David H.

AU - Gertz, Morie

PY - 2003/11/15

Y1 - 2003/11/15

N2 - The outcome of phtients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS). Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.

AB - The outcome of phtients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS). Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.

UR - http://www.scopus.com/inward/record.url?scp=0242579413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242579413&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-01-0073

DO - 10.1182/blood-2003-01-0073

M3 - Review article

C2 - 12893762

AN - SCOPUS:0242579413

SN - 0006-4971

VL - 102

SP - 3469

EP - 3477

JO - Blood

JF - Blood

IS - 10

ER -

Transplantation for multiple myeloma: Who, when, how often?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this